Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
Related VRX
Ackman Boosts Stake In Valeant; Still Appears To Be Passive
Benzinga's M&A Chatter for Monday March 16, 2015
Hyperion Therapeutics is an attractive takeover target says analyst (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...